sponsored
PatientsVille.com Logo

PatientsVille

Prednisolone Medical Research Studies

Up-to-date List of Prednisolone Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Prednisolone Medical Research Studies

Rank Status Study
1 Unknown  Prednisolone Priming Study in Patients With Chronic Hepatitis B
Condition: Chronic Hepatitis B
Interventions: Drug: Prednisolone;   Drug: Placebo priming
Outcome Measure: The primary endpoint will be the 1-year HBe-Ag seroconversion rate with or without Prednisolone priming.
2 Unknown  Prednisolone and Acupuncture in Bell's Palsy: a Randomised, Placebo-controlled, Multicentre Trial in China
Condition: Bell's Palsy
Interventions: Drug: Prednisolone;   Device: acupuncture
Outcome Measures: Assessment of Facial function;   Neurology examination;   registration of ipsilateral pain
3 Unknown  Efficacy of Moxifloxacin/Prednisolone in Prevention of Post Surgery Inflammation
Condition: Eye Infection/Inflammation Other
Interventions: Drug: moxifloxacin 0,5% + Prednisolone 1%;   Drug: moxifloxacin/Prednisolone combination
Outcome Measures: Day 15 Evaluation of Anterior Chamber;   day 15 physician´s follow-up impression of inflammatory reaction score
4 Unknown  Prednisolone Pharmacokinetics in Severe Asthma
Condition: Asthma
Intervention: Drug: Prednisolone
Outcome Measures: serum Prednisolone levels over 24 hours;   change in FEV1 24 hours post Prednisolone;   changes in eNO, sputum eosinophils and inflammatory mediators over 24 hours;   difference between day 1 and day 14 in serum Prednisolone levels;   difference in FEV1 between day 1 and day 14;   difference in inflammatory markers between day 1 and day 14;   changes in asthma control symptoms before and after treatment
5 Unknown  Biomarkers of Lupus Disease: Serial Biomarker Sampling in Patients With Active Systemic Lupus Erythematosus (SLE)
Condition: Systemic Lupus Erythematosus
Interventions: Drug: Depomedrol;   Other: Blood drawing only;   Drug: Methotrexate and depomedrol;   Drug: Mycophenolate mofetil and depomedrol
Outcome Measures: To determine major biomarker patterns in lupus patients flaring on minimal background medications and compare to those flaring on typical background meds used in clinic and clinical trials;   Biomarkers of steroid efficacy and toxicity;   validation of disease activity and flare instruments in development;   Patient reported outcomes and validation of new lupus specific quality of life and patient reported outcome measures
6 Unknown  Ciclosporin in the Management of New Type 1 Reactions in Leprosy
Condition: Leprosy
Interventions: Drug: Ciclosporin;   Drug: Prednisolone
Outcome Measures: improvement in nerve function;   incidence of adverse effects;   Skin lesion inflammation improvement;   rate of improvement of reaction;   Time to next reactional episode;   extra Prednisolone needed to control reaction
7 Recruiting Tacrolimus Versus Prednisolone for the Treatment of Minimal Change Disease
Condition: Minimal Change Disease
Interventions: Drug: tacrolimus;   Drug: Prednisolone
Outcome Measures: Proportion of patients achieving complete remission from nephrotic syndrome (normalisation of serum albumin and urine PCR <50 units) at 8 weeks;   Proportion of patients achieving complete remission from nephrotic syndrome at 16 and 24 weeks;   Proportion of patients achieving remission who then relapse;   Nature severity and frequency of adverse events;   change in baseline glomerualr filtration rate
8 Unknown  Efficacy and Tolerability of Prednisolone Acetate 0.5% Cream Versus Betamethasone Valerate 0.1% Cream in Cortisosensitive Dermatosis
Conditions: Dermatitis, Atopic;   Dermatitis, Contact;   Dermatitis, Seborrheic;   Psoriasis
Interventions: Drug: 0.5% Prednisolone acetate cream;   Drug: 0.1% betamethasone valerate cream
Outcome Measures: Evaluate efficacy and safety of 0.5% Prednisolone cream in comparison to 0.1% betamethasone cream in the treatment of corticosensitive dermatosis.;   Evaluate physicians' and patients' perception of the efficacy and tolerability of treatment.
9 Recruiting Addition of Pyridoxine to Prednisolone in Infantile Spasms
Condition: Infantile Spasms
Interventions: Drug: Pyridoxine plus Prednisolone;   Drug: Prednisolone
Outcome Measures: Proportion of children who achieved complete cessation spasm for at least 48 hours as per parental reports at the end of 2 weeks in both the groups.;   • Proportion of children who achieved more than 50 % reduction of clinical spasms as per parental reports at the end of 2 weeks
10 Unknown  Ciclosporin in the Management of Chronic or Recurrent Erythema Nodosum Leprosum
Condition: Leprosy
Interventions: Drug: Prednisolone;   Drug: ciclosporin
Outcome Measure:
11 Unknown  A Proof of Concept Study to Determine the Local Delivery and Efficacy of Nanocort
Condition: Atherosclerosis
Interventions: Drug: Nanocort;   Drug: MethylPrednisolone;   Drug: Placebo
Outcome Measures: Quantity of PEG liposomes in the atherosclerotic plaque and/ or in atherosclerotic macrophages as determined with a PEG antibody quantitative sandwich ELISA.;   Differences between TNF-alpha levels in the supernatant of isolated macrophages from the atherosclerotic tissue as determined by quantitative sandwich ELISA;   Concentration of corticosteroids in plaque.
12 Unknown  Oral Prednisolone in Severe Acute Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)
Condition: COPD Exacerbation
Interventions: Drug: Prednisolone;   Drug: usual care
Outcome Measures: ICU mortality rate;   Length of MV (and ventilatory free days)
13 Unknown  Ciclosporin in the Management of New Erythema Nodosum Leprosum
Condition: Leprosy
Interventions: Drug: Ciclosporin;   Drug: Prednisolone
Outcome Measures: time to relapse of ENL after initial control of symptoms;   time, in hours, to control initial episode of ENL relapse from time of starting anti-reactional medication;   time, in days, to ENL relapse from date of stopping anti-reactional medication
14 Recruiting Comparison of the Effectiveness of Two Different Dosages of Cortisone Compared to Placebo in Rheumatoid Arthritis
Condition: Progression of Rheumatoid Arthritis
Interventions: Drug: Prednisolone;   Drug: Placebo
Outcome Measures: Progression of radiographic damage after one year as quantified by the van der Heijde modification of the Sharp score (SHS). Determined at baseline and after one year.;   Percentage of patients in remission;   Changes of functional capacity;   Patient's assessment of disease activity
15 Recruiting Propranolol Versus Prednisolone for Treatment of Symptomatic Hemangiomas
Condition: Hemangioma of Infancy
Interventions: Drug: propranolol;   Drug: Prednisolone
Outcome Measures: reduction in size of hemangioma;   Tolerability of medication
16 Recruiting A Randomized Study of IVIG vs. IVIG With High Dose MethylPrednisolone in Childhood ITP.
Condition: Immune Thrombocytopenic Purpura
Interventions: Drug: MethylPrednisolone and IVIG;   Drug: Placebo and IVIG
Outcome Measures: The rapidity of rise in Platelet Count;   Days to PC falling to < 20 x 109/L;   Adverse Effects of therapy;   Quality of life changes over time and between the treatment groups
17 Unknown  Pilot Study of How Children With Asthma Exacerbations Metabolize Prednisone
Condition: Asthma Exacerbation
Intervention: Drug: Prednisolone and prednisone
Outcome Measure: pharmacokinetic profile of prednisone and Prednisolone
18 Unknown  Clinical Efficacy of the Drug Ster® Compared With Predfort® in Control of Postoperative Inflammation in Cataract Surgery
Conditions: Inflammation;   Cataract Surgery
Interventions: Drug: Ster;   Drug: Pred Fort
Outcome Measures: Comparison of clinical efficacy between the test and comparator drugs by measuring periodic scores of efficacy in established clinical parameters.;   Comparison of safety data observed during the study period by assessing frequency and intensity of adverse reactions, compared statistically between groups.
19 Recruiting Efficacy and Safety of MethylPrednisolone Per os Versus IV for the Treatment of Multiple Sclerosis (MS) Relapses
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: methylPrednisolone PO;   Drug: methylPrednisolone IV
Outcome Measure: At least 1 point-reduction on Kurtzke functional scale
20 Recruiting Addition of Prednisolone and Heparin in Patients Undergoing Controlled Ovarian Hyperstimulation (COH) for In Vitro Fertilization (IVF) With Failed IVF Cycles
Condition: Infertility
Interventions: Drug: Prednisolone and Heparin during COH for IVF;   Drug: COH for IVF
Outcome Measures: live birth rate;   clinical pregnancy rate

These studies may lead to new treatments and are adding insight into Prednisolone etiology and treatment.

A major focus of Prednisolone research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Prednisolone